AIM Vaccine Co., Ltd. (Stock code 06660.HK), committing to develop and manufacture top quality vaccines to safeguard the health of the world, was founded in 2011 and registered in Beijing. As a major vaccine company in China, AIM Vaccine cover the full value chain from research and development to manufacturing and to commercialization. AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, and is one of the first two human vaccine companies in the PRC that have been granted permission under the Fourteenth Five Year Plan of the PRC to build a P3 Lab.